Wednesday, October 03, 2018 - Sunday, October 07, 2018
San Francisco, CA
Posters for Venatorx's lead clinical antibacterial candidate, cefepime/VNRX-5133, will be presented on Friday, October 5, 2018 in S Poster Hall from 12:30pm to 1:45pm PT.
President and CEO, Christopher J. Burns, Ph.D., will present attendees with an overview of Venatorx’s pipeline and its unique operating model of leveraging non-dilutive funding to maximize investor dollars on Monday, May 21, 2018 at 8:00am ET in Ballroom V at the Grand Hyatt New York.
Tony Meehan, Ph.D., Senior Vice President, Business and Corporate Development, is participating on a panel entitled, "Partnering with big pharma - Will you hit the jackpot or lose it all?" on Thursday, May 10, 2018 at 3:00pm ET at the Hilton Philadelphia City Avenue.
Saturday, April 21, 2018 - Tuesday, April 24, 2018
Madrid, Spain
Fourteen poster presentations, including four oral sessions, will feature Venatorx's lead clinical antibacterial candidate, cefepime/VNRX-5133, at ECCMID in Madrid, Spain. In addition, Venatorx’s President and CEO, Christopher J. Burns, Ph.D., will present a brief overview about the Company’s R&D pipeline during Pipeline Corner on April 23, 2013 beginning at 12:30pm CET in Hall Y.
Wednesday, April 04, 2018 - Friday, April 06, 2018
Washington, DC
Christopher J. Burns, Ph.D., President and CEO, will participate on a panel entitled, "Panel – Man vs. Microbe," which will take place on April 5, 2018 at 10:30am ET at the St. Regis Hotel in Washington, DC.
Christopher J. Burns, Ph.D., President and CEO, will present Venatorx Pharmaceuticals' lead clinical antibacterial candidate, VNRX-5133, during the First-Time Disclosure of Clinical Candidates Symposium on March 21, 2018 at 3:15pm CT in New Orleans, LA. The oral presentation is entitled, “Discovery of VNRX-5133: A broad-spectrum serine- and metallo-beta-lactamase inhibitor (BLI) for carbapenem-resistant bacterial infections (“superbugs”).”
